This retrospective analysis reviewed the outcomes and management of conjunctival carcinomas defined as ≤0.2mm invasion of the chorion (miSCC) or over (SCC). Of 39 SCC and 15 miSCC patients, mitomycin was administered in 93.3% and 20.5% of miSCC and SCC, respectively (p<0.001). Proton therapy was used in 0% and 92.0% of miSCC and SCC respectively (p<0.001).

The 24-month incidence of local relapse was 14.8% including 20% and 12% for miSCC and SCC, respectively (p=0.079). Irradiation was the only prognostic factor associated with a lower risk for local relapse. This study concluded that miSCC had slightly worse relapse rates compared with SCC. Post-operative proton therapy used in SCC only, was associated with a lower risk for relapse.